Retinal Vein Occlusion (RVO) Treatment Market Analysis

Retinal Vein Occlusion Treatment Market Analysis

Based on the condition type, the market is categorized into branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). The CRVO segment is set to lead the market, accounting for the largest revenue of USD 1.5 billion, anticipating its dominance throughout the forecast period with a CAGR of 5.7%.
 

• CRVO occurs by the blockage of the main retinal vein, typically due to thrombosis. Its pathogenesis involves retinal vein compression and vascular endothelial damage, leading to complications like retinal neovascularization and macular edema. The complications associated with the condition emerged as the need for an effective therapy line driving the market demand.
   
• Also, the growing burden of CRVO has boosted the R&D efforts, leading to the development of targeted therapies and innovative treatment modalities specifically tailored to address the challenges, further solidifying the segment dominance in the market.
   
• For instance, 3SBio's anti-VEGF monoclonal antibody, 601A, is currently undergoing Phase I/IIa clinical trials, offering promising prospects for CRVO therapy with its potential to address the underlying mechanisms and alleviate associated symptoms. Thus, growing research efforts to cater to the need for advanced therapeutic options further solidify the segment dominance.
   

Based on treatment type, the retinal vein occlusion treatment market is classified into anti-VEGF therapy, corticosteroids, laser therapy, and other treatment types. The anti-VEGF therapy segment holds the largest market share of 67.6% in 2023 and is expected to maintain dominance throughout the analysis period.
 

• The advent of anti-VEGF therapy marked a significant breakthrough in treating RVO, including age-related macular degeneration. The studies have reported that anti-VEGF therapy tends to prevent vision loss along with sustained vision improvements lasting up to five years. Similarly, the increasing emphasis on ophthalmology drugs driven by rising awareness of retinal conditions has prompted major market players to prioritize the development and approval of innovative therapies tailored to address specific challenges, thereby expanding opportunities within the sector.
   
• For instance, in May 2024, Biocon Biologics Ltd., a subsidiary of Biocon Ltd, obtained U.S. Food and Drug Administration (US FDA) approval for Yesafili, a VEGF inhibitor biosimilar to EYLEA (aflibercept) in the U.S. Yesafili, is intended for various ophthalmology conditions including neovascular (wet AMD) age-related macular degeneration, RVO-associated macular edema, diabetic macular oedema (DME), and myopic (choroidal neovascularization) CNV. The approval marked a significant expansion of the ophthalmology therapeutics in the U.S. market.
   
• Thus, ongoing R&D efforts aimed at enhancing anti-VEGF treatments further solidify their position as the preferred choice for managing RVO, thereby driving their dominance within the market landscape.
   

Based on medication type, the retinal vein occlusion treatment market is segmented into branded and generics. In 2023, the branded segment is expected to reach USD 2.2 billion by 2032.

• Branded medications often hold a strong brand recognition, physician trust, and established efficacy profiles, which contribute to their preferential use by healthcare providers. Also, branded drugs may benefit from extensive marketing efforts and patient loyalty programs, further solidifying their market share. These factors, coupled with limited competition from generic alternatives, enable branded medications to maintain their stronghold and dominance within the market landscape.
   
• Furthermore, available of branded corticosteroids in the market will foster the segment growth. These drugs offer the advantage of addressing key components of RVO's pathophysiology, including stabilizing the blood-retina barrier and reducing vascular permeability and macular edema by inhibiting inflammatory mediators. Therefore, with increasing research on potential treatments, significant market growth is anticipated.
   

Based on the end-user, the retinal vein occlusion treatment market is segmented into hospitals, ophthalmic clinics, ambulatory surgical centers (ASCs), and academic and research institutes. The hospital segment is projected to exhibit CAGR of 5.6% during the analysis period.
 

• Hospitals are major users of retinal vein occlusion treatment for various medical procedures, including surgeries, dental treatments, and emergency care. Their consistent demand for retinal vein occlusion treatment in bulk quantities, coupled with their preference for high-quality and reliable pharmaceutical products, has contributed to the segment's dominance.
   
• Additionally, hospitals often have established procurement channels and partnerships with pharmaceutical suppliers, further solidifying their position in the market.
   

The U.S. dominated the North American retinal vein occlusion treatment market accounting for USD 858.5 million in 2023 and is anticipated to show considerable growth over the analysis period.
 

• The U.S. holds a prominent position due to the high prevalence of diabetes and hypertension, major risk factors for RVO. For instance, as per the Centers for Disease Control and Prevention (CDC), approximately 12 million individuals aged 40 and older experienced vision impairment in the U.S. Similarly, favorable reimbursement policies are anticipated to augment market expansion. In the U.S., the healthcare reimbursement framework extended coverage to approximately 84% of the population, with public (26%) or private (70%) health insurance. Thus, growing prevalence coupled with favorable reimbursement policies fuels the treatment demand.
   
• Further, the presence of key players, academic institutions, and clinical trial sites fosters advancements in RVO management and therapeutic approaches, thereby solidifying the country’s prominence in the North American market.
   

Germany exhibited a high growth potential in the European retinal vein occlusion treatment market.
 

• Germany boasts a robust healthcare infrastructure and advanced medical facilities, facilitating widespread access to RVO diagnosis and treatment in Europe. The country is renowned for its strong research capabilities coupled with the presence of research institutions and academic centers, driving innovation in RVO therapies through clinical trials and collaborative efforts further solidifying the country’s prominence in the European market.
   
• For instance, a research study featured in Nature in January 2023 assessed a novel personalized 2mg aflibercept treatment regimen for individuals with treatment for BRVO accompanied by macular edema. Such initiatives are poised to propel the market growth.
   

The Asia Pacific retinal vein occlusion treatment market is poised for rapid growth with a CAGR of 6.3% during the forecast period.
 

• The Asia Pacific region offers substantial growth potential in the market driven by factors such as the well-established healthcare infrastructure in countries like Japan, and ongoing advancements in India and China. As most countries in this region are developing economies, there is a swift adoption of innovative therapies.
   
• Moreover, with the rising prevalence of eye disorders in the Asia Pacific region, governments are prioritizing support for diagnostics and treatment, aiming to curtail disease progression and enhance early detection. These factors are poised to explore opportunities for the Asia Pacific region in the market.